| 1 |
35238644 | Activation of Rictor/mTORC2 signaling acts as a pivotal strategy to protect against sensorineural hearing loss. | 2022 Mar 8 |
1 |
| 2 |
34126157 | Implication of BAG5 downregulation in metabolic reprogramming of cisplatin-resistant ovarian cancer cells via mTORC2 signaling pathway. | 2021 Aug |
1 |
| 3 |
31744897 | Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment. | 2020 Feb |
2 |
| 4 |
32508971 | EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin. | 2020 |
1 |
| 5 |
32528729 | Loss of Rictor in tubular cells exaggerates lipopolysaccharide induced renal inflammation and acute kidney injury via Yap/Taz-NF-κB axis. | 2020 |
1 |
| 6 |
33144587 | Establishment and characterisation of testicular cancer patient-derived xenograft models for preclinical evaluation of novel therapeutic strategies. | 2020 Nov 3 |
1 |
| 7 |
24451322 | Rictor/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury. | 2014 Jul |
2 |
| 8 |
24840134 | Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis. | 2014 Jul |
1 |
| 9 |
23528835 | Sustained overexpression of Redd1 leads to Akt activation involved in cell survival. | 2013 Aug 19 |
1 |
| 10 |
23838676 | A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. | 2013 Oct |
1 |
| 11 |
24086535 | The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells. | 2013 |
1 |
| 12 |
22586651 | mTORC 2:1 for chemotherapy sensitization in glioblastoma. | 2011 Nov |
1 |